This drug may cause temporary blurred vision or other visual disturbances, if affected do not drive or operate machinery.
Monitor intraocular pressure.
Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.
Description: Brinzolamide is a carbonic anhydrase inhibitor that decreases secretion of aqueous humour thus reducing intraocular pressure. Pharmacokinetics: Absorption: Absorbed into systemic circulation. Distribution: Brinzolamide and metabolites: Accumulates in RBCs and bind to carbonic anhydrase. Plasma protein binding: Approx 60%. Metabolism: Metabolised to N-desethyl brinzolamide. Excretion: Via urine as unchanged drug and metabolites.
Anon. Brinzolamide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/10/2014.Azopt Suspension (Alcon Laboratories, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/10/2014.Buckingham R (ed). Brinzolamide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/10/2014.McEvoy GK, Snow EK, Miller J et al (eds). Brinzolamide (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/10/2014.